Competitive intelligence on
small-molecule drugs and
the 80,000 global patents
covering them

Start your free trial now

No commitment — No credit card required

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: KAPVAY

« Back to Dashboard

Summary for Tradename: KAPVAY

Patents:1
Applicants:1
NDAs:1
Suppliers: see list1

Pharmacology for Tradename: KAPVAY

Clinical Trials for: KAPVAY

Effect of Intrathecal Clonidine in Hypertensive Subjects With Poorly Controlled Blood Pressure
Status: Completed Condition: Hypertension

Efficacy & Safety of KAPVAYâ„¢ Extended-Release in Children & Adolescents With Attention Deficit Hyperactivity Disorder
Status: Completed Condition: Attention Deficit Hyperactivity Disorder

Transdermal Clonidine in the Treatment of Severe Hyperemesis Gravidarum
Status: Completed Condition: Hyperemesis Gravidarum

Bioequivalence of Two Transdermal Clonidine Administrations in Healthy Volunteers
Status: Completed Condition: Healthy

Safety of Clonidine in Infants With Hypoxic Ischemic Encephalopathy During Therapeutic Hypothermia
Status: Not yet recruiting Condition: Encephalopathy, Hypoxic-Ischemic

The Effect of Clonidine-enhanced Sedation on Delirium in Ventilated Critically Ill Patients
Status: Not yet recruiting Condition: Delirium

Comparison of Epidural Fentanyl and Clonidine for Breakthrough Pain
Status: Not yet recruiting Condition: Labor Pain

Epidural Clonidine for Lumbosacral Radiculopathy
Status: Terminated Condition: Lumbar and Other Intervertebral Disc Disorders With Radiculopathy

Comparison of Different Doses of Clonidine to Fentanyl as an Adjuvant to Bupivacaine 0.5% for Spinal Anesthesia
Status: Withdrawn Condition: Full Term Pregnant Patients; Undergoing Lower Segment Caesarian Section

Clonidine Versus Adenosine to Treat Neuropathic Pain
Status: Completed Condition: Pain

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Concordia Pharms Inc
KAPVAY
clonidine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022331Sep 28, 2010RXYes5,869,100<disabled>Y<disabled>
Concordia Pharms Inc
KAPVAY
clonidine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022331Sep 28, 2010RXNo5,869,100<disabled>Y<disabled>
Concordia Pharms Inc
KAPVAY
clonidine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022331Sep 28, 2010RXYes<disabled><disabled>
Concordia Pharms Inc
KAPVAY
clonidine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022331Sep 28, 2010RXNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access , or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: KAPVAY

Drugname Dosage Strength RLD Submissiondate
clonidine hydrochlorideExtended-release Tablets0.1 mg and 0.2 mgKapvay3/4/2011
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc